Skip to main content
CGEM
NASDAQ Life Sciences

Cullinan's CLN-049 Secures FDA Orphan Drug Designation for Relapsed/Refractory AML

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$15.24
Mkt Cap
$913.881M
52W Low
$5.68
52W High
$16.74
52W Position info
168% above low
Off High info
9.0% below high
Rel. Volume info
2.2× avg
Market data snapshot near publication time

CGEM has more than doubled off its 52-week low of $5.68 on elevated volume (2.2× avg).

Summary

Cullinan Therapeutics announced that its investigational FLT3xCD3 T cell engager, CLN-049, has received FDA Orphan Drug Designation for relapsed/refractory Acute Myeloid Leukemia (AML). This designation provides significant development incentives, including tax credits, user fee exemptions, and potential seven years of market exclusivity upon approval, which de-risks the development pathway for CLN-049. This positive regulatory milestone for a pipeline asset is important, especially following the company's recent Q1 2026 report which indicated a significantly reduced cash runway. Investors will now monitor the progress of CLN-049 through its ongoing Phase 1 studies and look for further clinical data readouts.

At the time of this announcement, CGEM was trading at $15.24 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $913.9M. The 52-week trading range was $5.68 to $16.74. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

CGEM - Latest Insights

CGEM
Oct 19, 2026, 7:00 AM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $13.35
Real-time Price: $11.51 info
Change: -$1.84 (-14%) info
Market Cap: $727.852M info
CGEM
Oct 01, 2026, 7:35 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $14.55
Real-time Price: $11.51 info
Change: -$3.04 (-21%) info
Market Cap: $727.852M info
CGEM
Sep 24, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $16.88
Real-time Price: $11.51 info
Change: -$5.37 (-32%) info
Market Cap: $727.852M info
CGEM
Sep 14, 2026, 7:29 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $20.60
Real-time Price: $11.51 info
Change: -$9.09 (-44%) info
Market Cap: $727.852M info
CGEM
Sep 13, 2026, 7:15 PM EDT
Source: BusinessWire
Importance Score:
8
Price at Filing: $21.11
Real-time Price: $11.51 info
Change: -$9.60 (-45%) info
Market Cap: $727.852M info